A Randomized, Double-Blinded, Safety and Pharmacokinetic Study of Escalating Single Doses of Hepalatide in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Hepalatide (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Shanghai HEP Pharmaceutical
- 21 Jul 2016 Status changed from active, no longer recruiting to completed.
- 22 Apr 2016 Planned End Date changed from 1 Feb 2016 to 1 Aug 2016.
- 22 Apr 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jul 2016.